Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
Standard interferon plus ribavirin may leads to higher treatment discontinuation compared with standard interferon alone (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · patients on HD with HCV infection
Standard interferon showed no clear difference in treatment discontinuation compared with placebo or control (moderate certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Oral alkylating agents ± steroids may leads to higher adverse events ‐ temporary/permanent discontinuation or… compared with placebo/no treatment/steroids (low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ temporary or permanent… compared with alkylating agents ± steroids (very low certainty).
1 finding from 1 review
Adverse events ‐ temporary or permanent discontinuation/hospitalisation at final · primary membranous nephropathy in adults with nephrotic syndrome
Immunosuppressive treatment probably leads to higher adverse events: temporary/permanent discontinuation or… compared with placebo/no treatment/non‐immunosuppressive supportive treatment (moderate certainty).
1 finding from 1 review
Adverse event causing death or study drug discontinuation · adults with renal vasculitis for maintenance therapy
Azathioprine showed no clear difference in adverse events causing death or study drug discontinuation compared with methotrexate (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · adults with renal vasculitis for maintenance therapy
Antibiotics showed no clear difference in adverse events causing study drug discontinuation compared with placebo (low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review